



(43) International Publication Date
 6 December 2001 (06.12.2001)

PCT

(10) International Publication Number
WO 01/092299 A3

(51) International Patent Classification⁷: **C12N 15/86**,
 15/34, 5/10, C07K 14/075, C12N 7/04

(21) International Application Number: **PCT/EP01/06286**

(22) International Filing Date: **1 June 2001 (01.06.2001)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
 09/585,344 **2 June 2000 (02.06.2000)** **US**
 60/270,555 **22 February 2001 (22.02.2001)** **US**

(72) Inventors; and
 (75) Inventors/Applicants (for US only): **JAKUBCZAK, John, Leonard** [US/US]; 12926 Summit Ridge Terrace, Germantown, MD 20874 (US). **ROLLENCE, Michele, Lynette** [US/US]; 11 Valley Park Court, Damascus, MD 20872 (US). **STEWART, David, A.** [US/US]; 6023 Kennard Court, Eldersburg, MD 21784 (US). **STEVENSON, Susan, C.** [US/US]; 10974 Horseshoe Drive, Frederick, MD 21701 (US). **HALLENBECK, Paul, L.** [US/US]; 7461 Rosewood Manor Lane, Gaithersburg, MD 20882 (US). **IDAMAKANTI, Neeraja** [CA/US]; 722 Clopper Road, Apartment 11, Gaithersburg, MD 20878 (US). **KALEKO, Michael** [US/US]; 8 Hearthstone Court, Rockville, MD 20854 (US). **SMITH, Theodore** [US/US]; 3346 Knolls Parkway, Ijamsville, MD 21754 (US).

(71) Applicant (for all designated States except AT, US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).


(74) Agent: **BECKER, Konrad**; Novartis AG, Corporate Intellectual Property, Patent & Trademark Dept., CH-4002 Basel (CH).

(71) Applicant (for AT only): **NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H.** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,**

[Continued on next page]

(54) Title: **ADENOVIRUS PARTICLES WITH MUTAGENIZED FIBER PROTEINS**



(57) Abstract: This invention relates to mutated adenoviral fiber proteins and adenovirus particles containing such proteins. It further relates to polynucleotides encoding the proteins and vectors containing polynucleotides. It also relates to methods for making and using the adenoviral particles. With the mutated fiber proteins, the adenovirus particles no longer bind to their natural cellular receptor. They can then be "retargeted" to a specific cell type through the addition of a ligand to the virus capsid, which causes the virus to bind to and infect such cell. Specific fiber mutations are listed, which ablate binding to the natural receptor. Adenovirus particles with certain fiber mutations were found to enhance gene transfer to and expression in liver as compared to viral particles with wild-type fiber.



WO 01/092299 A3

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/86 C12N15/34 C12N5/10 C07K14/075 C12N7/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

SEQUENCE SEARCH, CHEM ABS Data, EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 15823 A (GENVEC INC) 23 March 2000 (2000-03-23) claims 4,5; tables 1,2 ---	1-6, 8-11, 13-16, 18-32, 52-54, 59,61,62
X	WO 98 44121 A (MEHTALI MAJID ;LEGRAND VALERIE (FR); TRANSGENE SA (FR); BOULANGER) 8 October 1998 (1998-10-08) claims 4,8-10 --- -/--	1-5, 8-11, 13-16, 18-32, 52-54, 59,61,62

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

15 April 2003

Date of mailing of the international search report

01.07.2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Lonnoy, 0

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 98 50053 A (GENETIC THERAPY INC ; STEVENSON SUSAN C (US); GORZIGLIA MARIO (US);) 12 November 1998 (1998-11-12) ---	
A	WO 98 07865 A (GENVEC INC) 26 February 1998 (1998-02-26) -----	

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0015823	A	23-03-2000	AU 5819499 A 03-04-2000
			CA 2342396 A1 23-03-2000
			EP 1112372 A1 04-07-2001
			JP 2002525065 T 13-08-2002
			WO 0015823 A1 23-03-2000
			US 6455314 B1 24-09-2002
WO 9844121	A	08-10-1998	FR 2761688 A1 09-10-1998
			FR 2761689 A1 09-10-1998
			AU 741728 B2 06-12-2001
			AU 7054798 A 22-10-1998
			EP 0991763 A1 12-04-2000
			WO 9844121 A1 08-10-1998
			JP 2001522236 T 13-11-2001
			US 6569677 B1 27-05-2003
WO 9850053	A	12-11-1998	AU 743051 B2 17-01-2002
			AU 7263298 A 27-11-1998
			EP 1015005 A1 05-07-2000
			JP 2002513290 T 08-05-2002
			NZ 500791 A 25-10-2002
			US 2002192187 A1 19-12-2002
			WO 9850053 A1 12-11-1998
			US 2002123147 A1 05-09-2002
WO 9807865	A	26-02-1998	US 5846782 A 08-12-1998
			AU 724189 B2 14-09-2000
			AU 1086897 A 19-06-1997
			AU 732770 B2 26-04-2001
			AU 4080497 A 06-03-1998
			BG 102554 A 30-04-1999
			BR 9612685 A 20-07-1999
			CZ 9801623 A3 14-10-1998
			EE 9800160 A 15-12-1998
			EP 0863987 A2 16-09-1998
			EP 0920514 A1 09-06-1999
			HU 0001120 A2 28-07-2000
			JP 2001503250 T 13-03-2001
			JP 11501219 T 02-02-1999
			NO 982417 A 06-07-1998
			NZ 323834 A 28-01-2000
			PL 327038 A1 09-11-1998
			SK 72298 A3 02-12-1998
			WO 9720051 A2 05-06-1997
			WO 9807865 A1 26-02-1998
			US 6465253 B1 15-10-2002
			US 6057155 A 02-05-2000
			US 6329190 B1 11-12-2001
			US 2002151027 A1 17-10-2002
			US 2003022355 A1 30-01-2003

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 27-30, 45-48, and 50-58, as far as they relate to in vivo methods, are directed to methods of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-6, 8-11, 13-16, 18-32, 52-54, 59, 61, 62 partially

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-6, 8-11, 13-16, 18-32, 52-54, 59, 61, 62 (all partially)

- 1.1. Claims: 1-6, 8-11, 13-16, 18-32, 52-54, 59, 61, 62 (all partially)

A mutated adenoviral fiber protein wherein at least aa 441 has been mutated; polynucleotide encoding said fiber; adenoviral particle comprising said fiber; methods and compositions relating thereto.

- 1.2. Claims: 1-6, 8-11, 13-16, 18-32, 52-54, 59, 61, 62 (all partially)

A mutated adenoviral fiber protein wherein at least aa 442 has been mutated; polynucleotide encoding said fiber; adenoviral particle comprising said fiber; methods and compositions relating thereto.

2. Claims: 7, 12, 17, 21-23 (all partially)

A mutated adenovirus serotype 5 fiber protein comprising at least a mutation at amino acid 460.

3. Claims: 7, 12, 17, 21-23 (all partially)

A mutated adenovirus serotype 5 fiber protein comprising a at least mutation at amino acid 509.

4. Claims: 7, 12, 17, 21-23 (all partially)

A mutated adenovirus serotype 5 fiber protein comprising a at least mutation at amino acid 510.

5. Claims: 7, 12, 17, 21-23 (all partially)

A mutated adenovirus serotype 5 fiber protein comprising a at least a mutation at amino acid 538.

6. Claims: 7, 12, 17, 21-23 (all partially)

A mutated adenovirus serotype 5 fiber protein comprising a at least mutation at amino acid 539.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

7. Claims: 33-51, 55-58, 60 (all totally) and 52-54, 61,
62 (all partially)

A mutated adenovirus serotype 5 fiber protein comprising mutations at amino acid positions 408 and 409; polynucleotide encoding said fiber; adenoviral particle comprising said fiber; methods and compositions relating thereto.

Please note that all inventions mentioned under item 1, although not necessarily linked by a common inventive concept, could be searched without effort justifying an additional fee.

ADENOVIRUS PARTICLES WITH MUTAGENIZED FIBER PROTEINS

Claims of WO0192299

- CLAIMS: 1. A mutated adenoviral fiber protein wherein at least one amino acid in the CD loop of a wild-type fiber protein of an adenovirus from subgroup C, D, or E, or the long wild-type fiber of an adenovirus from subgroup F, has been mutated to reduce or substantially eliminate the ability of said fiber protein to bind to the coxsackievirus-adenovirus receptor (CAR).
2. The mutated adenoviral fiber protein of claim 1, wherein said mutation substantially eliminates the ability of said protein to bind to said CAR.
3. The mutated adenoviral fiber protein of claim 2, wherein said fiber protein is an adenovirus serotype 5 fiber protein.
4. The mutated adenoviral fiber protein of claim 3, wherein said fiber protein contains at least one mutation at amino acid positions 441 and 442 of the wild-type fiber protein.
5. The mutated adenoviral fiber protein of claim 4, wherein said fiber protein further comprises a mutation at one or more of the following amino acid positions of the wild type fiber protein: 408, 409, 460, 509, 510, 538, and 539.
6. The mutated adenoviral fiber protein of claim 4, wherein said fiber protein further comprises at least one mutation at amino acid positions 408 and 409 of the wild-type fiber protein.
7. A mutated adenovirus serotype 5 fiber protein wherein said fiber protein comprises a mutation at one or more of the following amino acid positions of the wild-type fiber protein: 460, 509, 510, 538, and 539, wherein said mutation reduces or substantially eliminates the ability of said fiber protein to bind to CAR.
8. A polynucleotide encoding the protein of claim 1.
9. A polynucleotide encoding the protein of claim 3.
10. A polynucleotide encoding the protein of claim 4.
11. A polynucleotide encoding the protein of claim 5.
12. A polynucleotide encoding the protein of claim 7.
13. An adenoviral particle comprising the fiber protein of claim 1.
14. An adenoviral particle comprising the fiber protein of claim 3.
15. An adenoviral particle comprising the fiber protein of claim 4.
16. An adenoviral particle comprising the fiber protein of claim 5.
17. An adenoviral particle comprising the fiber protein of claim 7.
18. The adenoviral particle of claim 13 further comprising a targeting ligand included in a capsid protein of said particle.
19. The adenoviral particles of claim 18 wherein said capsid protein is the mutated adenoviral fiber protein.
20. The adenoviral particle of claim 19 further comprising at least one heterologous polynucleotide.
21. The adenoviral particle of any one of claims 14-17 further comprising a targeting ligand included in a capsid protein of said particle.

22. The adenoviral particle of claim 21 wherein said capsid protein is the mutated adenoviral fiber protein.

23. The adenoviral particle of claim 22 further comprising at least one heterologous polynucleotide.

24. An adenovirus packaging cell comprising the polynucleotide of claim 8.

25. A method of making the adenoviral particle of claim 13, comprising the stepsof : transferring the adenovirus genome to be packaged in said particle into the packaging cell of claim 24; culturing said packaging cell; and recovering an adenoviral particle produced by said cell.

26. A method of making the adenoviral particle of claim 18 comprising the stepsof : transferring the adenovirus genome to be packaged in said particle into a cell having adenovirus polynucleotides that provide proteins necessary for the replication, maturation, and packaging of said genome; culturing said cell under conditions permitting the production of said particle; and recovering an adenoviral particle produced by said cell.

27. A method of expressing a heterologous polynucleotide in a cell comprising infecting said cell with the adenoviral particle of claim 20.

28. The method of claim 27, wherein said cell is a mammalian cell.

29. The method of claim 28, wherein said mammalian cell is a primate cell.

30. The method of claim 29, wherein said primate cell is a human cell.

31. A composition comprising the adenoviral particle of claim 18 in a pharmaceutically acceptable carrier.

32. A composition comprising the adenoviral particle of claim 20 in a pharmaceutically acceptable carrier.

33. A mutated adenovirus serotype 5 fiber protein wherein said fiber protein contains mutations at amino acid positions 408 and 409 of the wild-type fiber protein.

34. The mutated fiber protein of claim 33, wherein said protein contains deletions at amino acid positions 408 and 409 of the wild-type fiber protein.

35. The mutated fiber protein of claim 33, wherein said protein contains amino acid substitutions at amino acid positions 408 and 409 of the wild-type fiber protein.

36. The mutated fiber protein of claim 35, wherein glutamic acid is substituted for serine at position 408 and alanine is substituted for proline at position 409 (SEQ ID NO: 4).

37. A polynucleotide encoding the protein of claims 33-36.

38. An adenoviral particle comprising the fiber protein of claims 33-36.

39. The adenoviral particle of claim 38, further comprising a targeting ligand included in a capsid protein of said particle.

40. The adenoviral particle of claim 39, further comprising at least one heterologous polynucleotide.

41. The adenoviral particle of claim 38, wherein at least one of the penton proteins of said particle has been modified to delete the RGD sequence.

42. An adenovirus packaging cell comprising the polynucleotide of claim 37.

43. A method of making the adenoviral particle of claim 38, comprising the steps of : transferring the adenovirus genome to be packaged in said particle into the packaging cell of claim 42; culturing said packaging cell; and recovering an adenoviral particle produced by said cell.

44. A method of making the adenoviral particle of claim 38, comprising the stepsof : transferring the

adenovirus genome to be packaged in said particle into a cell having adenovirus polynucleotides that provide proteins necessary for the replication, maturation, and packaging of said genome; culturing said cell under conditions permitting the production of said particle; and recovering an adenoviral particle produced by said cell.

45. A method of expressing a heterologous polynucleotide in a cell comprising infecting said cell with the adenoviral particle of claim 40.

46. The method of claim 45, wherein said cell is a mammalian cell.

47. The method of claim 45, wherein said cell is a primate cell.

48. The method of claim 45, wherein said cell is a human cell.

49. A composition comprising the adenoviral particle of claim 40 in a pharmaceutically acceptable carrier.

50. A method of enhancing adenoviral-mediated gene transfer to and expression in hepatocytes comprising the steps of administering adenoviral particles of claim 40 to said hepatocytes.

51. A method of enhancing adenoviral-mediated gene transfer to and expression in hepatocytes comprising the steps of: preparing an adenovirus particle comprising a mutated adenovirus serotype 5 fiber protein, wherein glutamic acid is substituted for serine at amino acid position 408 and alanine is substituted for proline at amino acid position 409, and further comprising a heterologous gene; and infecting hepatocytes with said adenovirus particle.

52. A method of expressing a protein in a mammal comprising the step of administering the adenoviral particle of claim 20 or claim 40 to said mammal, wherein said particle transduces a cell in said mammal and said heterologous polynucleotide expresses said protein in said cell.

53. The method of claim 52, wherein said mammal is a primate.

54. The method of claim 53, wherein said primate is a human.

55. A method of expressing a protein in the liver of a mammal comprising administering a sufficient amount of the adenoviral particles of claim 40 for said particles to transduce cells in the liver of said mammal.

56. The method of claim 55, wherein said amount comprises approximately 1 particle per kilogram of body weight to approximately 10¹³ particles per kilogram of body weight.

57. The method of claim 55, wherein said amount comprises approximately 10⁴ particles per kilogram of body weight to approximately 10¹² particles per kilogram of body weight.

58. The method of claim 55, wherein said amount comprises approximately 10⁸ particles per kilogram of body weight to approximately 10¹¹ particles per kilogram of body weight.

59. An adenoviral vector comprising the polynucleotide of any one of claims 8-12.

60. An adenoviral vector comprising the polynucleotide of claim 37.

61. The adenoviral particle of claims 13, 18, 20, 38, 39, 40, or 41, wherein said adenoviral particle is a replication conditional adenovirus.

62. The adenoviral particle of claim 61, wherein said adenovirus is an oncolytic adenovirus.

Data supplied from the esp@cenet database - Worldwide

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.